ArticleCancer reports (Hoboken, N.J.)2025
Correlation Between MRI and Histopathology in Assessing Treatment Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative Magnetic Resonance Imaging Results Are Concordant with Pathology Staging in Rectal Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- Correlation Between MRI and Histopathology in Assessing Treatment Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsRecognizing the predictive factors of response to chemoradiation is of utmost importance in patients with locally advanced rectal cancer (LARC). The study is designed to explore the correlation between post-neoadjuvant chemoradiation (nCRT) pathologic and MR-based tumor staging in LARC.
methodsPatients with non-metastatic LARC underwent contrast-enhanced pelvic MRI before and after treatment, received standard chemoradiation, and were evaluated for tumor response. Tumor regression grade (TRG) based on histopathology ranged from TRG0 to TRG3, while MR-based responses encompassed complete response, partial response, stable disease, and progressive disease. The primary endpoints were the correlation and agreement between post-nCRT histopathologic- and MR-based tumor staging. The secondary endpoints focused on predictive factors influencing the response to nCRT and assessing the effectiveness of MRI in identifying complete pathologic response (pCR).
resultsThe analysis showed a strong positive correlation (r = 0.86, p < 0.001) with moderate agreement (κ = 0.44) between post-nCRT MR- and histopathologic-based disease staging. According to multivariate analysis, initial tumor stage could predict clinical response to nCRT, and MR-based TRG could predict histopathologic response. MRI exhibited a specificity of 96.2%, sensitivity of 22.2%, positive predictive value of 50%, and negative predictive value of 88.1% in detecting pCR.
conclusionsThe study highlights the promising role of MRI in assessing treatment response in LARC, guiding clinical decision-making and potentially reducing the need for invasive procedures to evaluate treatment effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.